Recommendations for the Management and Treatment of Dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias

Overview

Journal CMAJ

Date 2000 Jun 2

PMID 10834048

Citations 45

Authors

J G Fodor

J J Frohlich

J J Genest Jr

P R McPherson

Affiliations

Soon will be listed here.

Citing Articles

Cardiorespiratory fitness estimations and their ability to predict all-cause mortality in patients with cardiovascular disease.

Peterman J, Rouleau C, Arena R, Aggarwal S, Wilton S, Hauer T Int J Cardiol Cardiovasc Risk Prev. 2022; 15:200154.

PMID: 36573187 PMC: 9789345. DOI: 10.1016/j.ijcrp.2022.200154.

Effect of nutrition education and traditional game-based physical activity interventions, on lipid profile improvement in overweight and obese children in West Java Indonesia.

Yulia C, Khomsan A, Sukandar D, Riyadi H Nutr Res Pract. 2021; 15(4):479-491.

PMID: 34349881 PMC: 8313393. DOI: 10.4162/nrp.2021.15.4.479.

Dyslipidaemia for patients with low-energy femoral neck fractures after the treatment of cancellous screws: a retrospective study with a 3-year minimum follow-up.

Zhang C, Zhu X, Pei G, Xu P, Zeng X, Zhang L BMC Musculoskelet Disord. 2017; 18(1):440.

PMID: 29126401 PMC: 5681794. DOI: 10.1186/s12891-017-1804-x.

Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.

Hallberg S, Banefelt J, Fox K, Mesterton J, Johansson G, Levin L Int J Clin Pract. 2016; 70(3):222-8.

PMID: 26799539 PMC: 4819716. DOI: 10.1111/ijcp.12769.

Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged?.

Can J Hosp Pharm. 2014; 67(3):246-9.

PMID: 24970946 PMC: 4071088. DOI: 10.4212/cjhp.v67i3.1363.

References

Larosa J, He J, Vupputuri S . Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999; 282(24):2340-6. DOI: 10.1001/jama.282.24.2340. View

CASTELLI W, Garrison R, Wilson P, Abbott R, Kalousdian S, Kannel W . Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986; 256(20):2835-8. View

Ornish D, Brown S, Scherwitz L, Billings J, Armstrong W, Ports T . Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990; 336(8708):129-33. DOI: 10.1016/0140-6736(90)91656-u. View

Buchwald H, VARCO R, Matts J, Long J, Fitch L, Campbell G . Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990; 323(14):946-55. DOI: 10.1056/NEJM199010043231404. View

Brown G, Albers J, Fisher L, Schaefer S, Lin J, Kaplan C . Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323(19):1289-98. DOI: 10.1056/NEJM199011083231901. View

Kane J, Malloy M, Ports T, Phillips N, DIEHL J, HAVEL R . Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990; 264(23):3007-12. View

Mack W, Pogoda J, SANMARCO M, Azen S, Blankenhorn D . Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990; 264(23):3013-7. View

Watts G, Lewis B, Brunt J, Lewis E, Coltart D, Smith L . Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992; 339(8793):563-9. DOI: 10.1016/0140-6736(92)90863-x. View

Assmann G, Schulte H . Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol. 1992; 70(7):733-7. DOI: 10.1016/0002-9149(92)90550-i. View

10.

Haskell W, Alderman E, Fair J, Maron D, Mackey S, Superko H . Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994; 89(3):975-90. DOI: 10.1161/01.cir.89.3.975. View

11.

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

12.

Kannel W, DAgostino R, Cobb J . Effect of weight on cardiovascular disease. Am J Clin Nutr. 1996; 63(3 Suppl):419S-422S. DOI: 10.1093/ajcn/87.6.1602. View

13.

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

14.

Grundy S, Balady G, Criqui M, Fletcher G, Greenland P, Hiratzka L . Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation. 1997; 95(9):2329-31. DOI: 10.1161/01.cir.95.9.2329. View

15.

Hopkins P, Wu L, Hunt S, James B, Vincent G, Williams R . Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997; 17(11):2783-92. DOI: 10.1161/01.atv.17.11.2783. View

16.

Grundy S . Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998; 81(4A):18B-25B. DOI: 10.1016/s0002-9149(98)00033-2. View

17.

Despres J . The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes Res. 1998; 6 Suppl 1:8S-17S. DOI: 10.1002/j.1550-8528.1998.tb00683.x. View

18.

Pedersen T, Olsson A, Faergeman O, Kjekshus J, Wedel H, Berg K . Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998; 97(15):1453-60. DOI: 10.1161/01.cir.97.15.1453. View

19.

Frohlich J, Fodor G, McPherson R, Genest J, Langner N . Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. Can J Cardiol. 1998; 14 Suppl A:17A-21A. View

20.

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View